OSE Immunotherapeutics Announces First Patient Dosed with Anti-PD1 Monoclonal Antibody OSE-279 in a Phase 1/2 Clinical Trial in Advanced Solid Tumors or Lymphomas
03/01/2023
T-cell activation through neo-epitopes Transforming tumor microenvironment suppressive cells into effector cells
Down regulating T effector cells to decrease immunological reactivity Up regulating regulatory T-cells to develop immune tolerance
Therapeutic vaccine Prophylactic vaccine Based on T-cells
Premier international pharma, clinical and academic collaborations to speed up the delivery of our product candidates to patients in need
To download the documents